Researchers at the School of Medicine have been awarded $13.7 million from the National Cancer Institute (NCI) to create new therapies for multiple myeloma, a cancer of the immune system. Led by Samuel Achilefu, PhD, (pictured) and Gregory Lanza, MD, PhD, at the newly created Center for Multiple Myeloma Nanotherapy, scientists will work to develop nanomaterials and drugs to treat the disease.
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer. The process, developed by scientists at Washington University School of Medicine in St. Louis, also may aid patients with leukemia or lymphoma.
Three scientists at Washington University School of Medicine in St. Louis and Siteman Cancer Center each will receive $900,000 in funding – $2.7 million total – over two years for their innovative approaches to fighting leukemia and other types of cancer.
Six researchers at Washington University are being honored as outstanding scientists by the Academy of Science-St. Louis. University recipients are faculty members Ralph Quatrano, Jennifer K. Lodge, Samuel Achilefu, Charles M. Hohenberg, Gautam Dantas and Steven Teitelbaum (right), who received a lifetime achievement award.
Researchers led by Samuel Achilefu, PhD, at the School of Medicine have devised a way to apply light-based therapy to deep tissues never before accessible. Instead of shining an outside light, they delivered light directly to tumor cells, along with a photosensitive source of free radicals that can be activated by the light to destroy cancer.
Samuel Achilefu, PhD, of the School of Medicine has won the St. Louis Award for 2014 for his work in creating cancer-visualizing glasses, which were used in surgeries for first time last year. He is the 87th person honored with the annual award since it was established in 1931.
High-tech glasses developed at the School of Medicine may help surgeons visualize cancer cells, which glow blue when viewed through the eyewear. The wearable technology was used during surgery for the first time Feb. 10 at Siteman Cancer Center.